Entos Pharmaceuticals develops genetic medicines using its proprietary, non-viral Fusogenix PLV delivery platform. The Fusogenix PLV platform is formulated with FAST proteins to enable direct fusion delivery of RNA, DNA and gene‑editing therapies and is described as combining the best aspects of viral and non‑viral approaches. Entos says the platform is suitable for a wide range of genetic medicines and is committed to advancing next‑generation therapies to improve patients' lives. The company will use CureDuchenne Ventures' initial $1M investment to create a muscle‑targeting therapeutic to deliver full‑length dystrophin for Duchenne muscular dystrophy (DMD). Entos plans to share information about the platform and its Duchenne program at the CureDuchenne 2025 FUTURES National Conference. Entos was founded in 2016 and is headquartered in Edmonton, Canada, with wholly owned U.S. and U.K. subsidiaries in San Diego and London. Entos Pharmaceuticals develops next-generation nucleic acid therapeutics using its proprietary Fusogenix PLV proteolipid vehicle platform. The Fusogenix PLV system uses FAST proteins to enable direct fusion delivery of nucleic acids to target cells. Entos plans to build a 103,000-square-foot R&D centre and a GMP biomanufacturing facility in Edmonton to develop, scale up, produce, and commercialize Fusogenix PLV therapeutics. The $198.5 million project is supported by $77.5 million in government funding. Entos has partnerships with Eli Lilly and collaborators including Oisin Biotechnologies, OncoSenX, and Aegis Life and aims to foster academic and industry collaborations in Canada. The company was founded in 2016 and is headquartered in Edmonton, with U.S. and U.K. subsidiaries in San Diego and London. Entos Pharmaceuticals is a clinical-stage genetic medicines company that uses its proprietary Fusogenix PLV platform to deliver RNA, DNA, and gene‑editing therapies. Its lead program, ENTLEP001, is a systemically administered investigational gene therapy designed to express native human leptin for the treatment of congenital generalized lipodystrophy (CGL); the candidate is intended to be durable and redosable. Preclinical studies in a leptin‑deficient mouse model produced clinically relevant leptin expression, normalization of glucose and insulin levels, and reduced weight gain and food intake. The company says the Fusogenix PLV platform combines aspects of viral and non‑viral approaches and published animal safety, efficacy, and biodistribution data in Cell in September 2024. Entos has stated plans to advance a second product into the clinic and has partnered with global companies including Eli Lilly. The company was founded in 2016 and is headquartered in Edmonton, Canada, with U.S. and U.K. subsidiaries in San Diego and London.

Total raised

$83M

Funding rounds

3

Latest round

Equity

Latest activity

May 2025